Clinical trials
Tumor clinical trials
Below are recruiting tumor clinical trials, each written for real people, not researchers. We’re tracking 3,416 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07233954Recruiting
Can Fluorescein Dye Help Remove Brain Tumors?
This study tests whether using a fluorescent dye called fluorescein (injected into a vein during surgery) helps neurosurgeons better see and remove aggressive brain or spinal cord tumors. It may lead to safer, more complete tumor removal.
MilanAges Any age - NCT07233928Recruiting
Breast cancer protein study in different subtypes
This trial takes a close look at the proteins inside breast cancer cells, using samples from people with different subtypes. It aims to better understand how each type behaves, which could help guide future treatments.
ToulouseAges 18 years+ - NCT07236177RecruitingEarly Phase 1
Enzyme test for early breast, lung, or pancreatic cancer
This study tests a new blood test that measures enzyme activity to detect localized cancer. It is for people with newly diagnosed, untreated breast, lung, or pancreatic cancer, as well as healthy volunteers.
PoitiersAges 18 years+ - NCT07238075RecruitingPhase 1
ADCX-020 for advanced or metastatic cancers
This trial tests a new drug, ADCX-020, for people with advanced solid tumors that have stopped responding to standard treatments. The drug targets cancer cells directly and may offer a new option when other treatments have failed.
Sydney, New South WalesAges 18 years+ - NCT07245095RecruitingPhase 2
Pre-medication for better views during upper endoscopy
This trial tests whether taking two medicines (N-acetylcysteine and simethicone) before an upper endoscopy helps the doctor see the stomach lining more clearly. It may be an option for people having their first endoscopy, without active bleeding.
Mexicali, Estado de Baja CaliforniaAges 18–99 - NCT07249060Recruiting
Interferon levels in cancer and autoimmune disease patients
This study looks at a protein called interferon in the blood of people with cancer who are starting immunotherapy, and people with certain autoimmune diseases (such as lupus, Sjögren's syndrome, scleroderma, or inflammatory myopathy). The goal is to compare interferon patterns and better understand immune responses.
Pamplona, NavarreAges 18 years+ - NCT07249775Recruiting
Study of new drug FID-022 for pancreatic cancer
This trial tests a new study drug called FID-022 for people with pancreatic cancer. It is a first-in-human study, meaning it is the first time this drug is being tested in people, and researchers want to see if it is safe and how it works.
Tampa, FloridaAges 18 years+ - NCT07250386RecruitingPhase 1
CEA-targeted CAR-T therapy for advanced solid tumors
This trial tests a new CAR-T cell therapy that targets CEA, a protein found on certain cancer cells. It's for people with advanced solid tumors like lung or breast cancer who have not responded to other treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT06541262RecruitingPhase 1/Phase 2
Silmitasertib plus chemo for relapsed solid tumors
This trial tests a new drug, silmitasertib, combined with standard chemotherapy for children and young adults with cancers that have come back or not responded to treatment. The goal is to see if this combination can shrink tumors or stop them from growing.
Birmingham, AlabamaAges Up to 30 years - NCT07000084RecruitingPhase 3
Testing gemcitabine with BCG for returning bladder cancer
This trial tests whether adding a chemotherapy drug called gemcitabine to the usual BCG therapy can help prevent bladder cancer from coming back again. If you have had BCG before and your cancer returned, this study might offer a more effective treatment option.
Birmingham, AlabamaAges 18 years+ - NCT01247597Recruiting
Study of DICER1-related tumor history in families
This study follows people affected by DICER1-related tumors (and sometimes family members) to better understand how these conditions develop over time. It may help families by improving knowledge and guiding genetic counseling and future care.
Bethesda, MarylandAges 1 month–99 years - NCT07169734RecruitingPhase 1/Phase 2
ALE.P03 for advanced CLDN1-positive solid tumors
This trial tests a new drug, ALE.P03, for people with advanced or metastatic solid tumors that have a certain protein (CLDN1). The drug is given alone (monotherapy) to see if it can shrink tumors or slow their growth.
Phoenix, ArizonaAges 18 years+ - NCT07488676RecruitingPhase 1/Phase 2
Study of ASP546C for stomach, pancreas, and other cancers
This trial tests a new drug called ASP546C in people with certain advanced cancers that have a specific marker (CLDN18.2). It aims to see if the drug can shrink or slow tumor growth.
Birmingham, AlabamaAges 18 years+ - NCT07258160RecruitingPhase 2
Cordycepin for low CD8+ cells in solid tumor patients
This trial tests a supplement derived from cordyceps mushrooms to see if it can raise low CD8+ immune cell levels in people who have had solid tumors. It may help strengthen your immune system after previous cancer treatments.
Suzhou, JiangsuAges 18 years+ - NCT07258186Recruiting
Endometrial cancer organoid study
This study creates miniature 3D versions of endometrial cancer tumors (organoids) from tissue samples taken during surgery. The goal is to better understand the disease and find personalized treatments.
Roma, RomaAges 18 years+ - NCT07260188Recruiting
Breast cancer organoids from patients before chemo
This study collects tumor tissue from breast cancer patients before they start chemotherapy to grow miniature versions of their tumors (organoids) in the lab. The goal is to understand how each tumor responds to treatment, which may help personalize future therapies.
Pavia, PVAges 18 years+ - NCT07261631RecruitingPhase 1
A study of a new radioactive drug for advanced solid tumors
This trial tests a new radioactive drug called [177Lu]Lu-DFC413 for people with certain advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target cancer cells with a specific marker seen on a special scan.
Montreal, QuebecAges 18–100 - NCT07263438RecruitingPhase 2
Trimipramine, atezolizumab, and bevacizumab for recurrent glioblastoma
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
Basel, BaselAges 18 years+ - NCT07263594RecruitingPhase 1/Phase 2
Study of DB-1324 for advanced stomach or bowel cancers
This trial tests a new drug called DB-1324 for people with advanced gastrointestinal cancers that have stopped responding to standard treatments. It targets a protein called CDH17 on cancer cells to slow or shrink the tumor.
Port Saint Lucie, FloridaAges 18 years+ - NCT07268183Recruiting
Estrogen changes and prolactinoma tumor size
This study looks at how changes in estrogen before diagnosis affect the growth of prolactin-secreting pituitary tumors (prolactinomas). The goal is to understand why some tumors are larger than others.
Bron, RhoneAges 18 years+ - NCT07269080RecruitingPhase 1
Radiation plus immunotherapy for advanced solid tumors
This trial tests whether adding targeted radiation to your metastatic tumors can help your immunotherapy work better. It is for people with advanced solid tumors that have spread to 3-10 spots and who have been on immunotherapy for at least 3 months.
Chicago, IllinoisAges 18 years+ - NCT07272512RecruitingPhase 4
Surufatinib for advanced neuroendocrine tumors
This trial tests the drug surufatinib in people with advanced neuroendocrine tumors. It is a real-world study, meaning it looks at how the drug works in everyday practice, and may help control tumor growth.
ShanghaiAges 18 years+ - NCT07273409Recruiting
Surgery for advanced pancreatic neuroendocrine tumors
This trial tests whether surgically removing as much of the tumor as possible (debulking) is better than not doing surgery for people with advanced pancreatic neuroendocrine tumors. It aims to see if this approach can improve outcomes.
GothenburgAges 18 years+ - NCT07274397Recruiting
Early brain scan study after glioblastoma surgery
This study tests whether it is safe and possible to do a special brain scan (nuclear imaging) within the first 3 days after surgery for glioblastoma. It may help doctors understand how well the tumor was removed and guide future treatments.
CréteilAges 18 years+
Hear when a new Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tumor?
- Yes. Clin2 currently lists 3,416 recruiting tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.